Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2009 - 2026)

Regeneron Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 727200000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 10.08% year-over-year to 727200000.0; the TTM figure through Mar 2026 stood at 4423400000.0 (down 1.69% YoY), while the FY2025 annual figure was 4504900000.0, up 2.09% from the prior year.
• Income from Continuing Operations was 727200000.0 for Q1 2026 at Regeneron Pharmaceuticals, down from 844600000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1460000000.0 in Q3 2025 to a low of 722000000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 1055100000.0 across 5 years, with a median of 973500000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 72.5% in 2022, then soared 47.9% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 1197100000.0 in 2022, then retreated by 3.13% to 1159600000.0 in 2023, then decreased by 20.86% to 917700000.0 in 2024, then dropped by 7.97% to 844600000.0 in 2025, then retreated by 13.9% to 727200000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 727200000.0 (Q1 2026), 844600000.0 (Q4 2025), and 1460000000.0 (Q3 2025), per Business Quant data.